About Assembly Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.assemblybio.com/
Frequently Asked Questions
What is the 52-week range for ASMB?
The 52-week high is $39.705 and the 52-week low is $21.795.
What is the P/E ratio for ASMB?
The P/E ratio data is currently unavailable.
What is the dividend yield for ASMB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -0.02%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -0.06%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.60.
Analyst Recommendation Trends
Wall Street analyst consensus for ASMB over the last few months:
Latest ASMB News
Best Momentum Stocks to Buy for September 17th
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
New Strong Buy Stocks for September 17th
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
5 Stocks With Recent Price Strength Buoyed by a Strong August
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going
Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-17 | Bjorkquist Jeanette M | -29 | $23.25 | $674 |
| 2026-06-04 | McHutchison John G | +8,000 | - | - |
| 2026-06-04 | Mahony Susan | +8,000 | - | - |
| 2026-06-04 | Johnson-Pratt Lisa | +8,000 | - | - |
| 2026-06-04 | Houghton Michael | +8,000 | - | - |
| 2026-06-04 | Consylman Gina | +8,000 | - | - |
| 2026-06-04 | ALTIG ANTHONY E | +8,000 | - | - |
| 2026-05-26 | GILEAD SCIENCES, INC. | +471,698 | $26.5 | $12,499,997 |
| 2026-03-30 | Bjorkquist Jeanette M | -16 | $27.49 | $440 |
| 2026-03-30 | Bjorkquist Jeanette M | -312 | $26.6502 | $8,315 |
| 2026-03-30 | White Nicole S | -9 | $27.49 | $247 |
| 2026-03-30 | White Nicole S | -188 | $26.6502 | $5,010 |
| 2026-03-29 | Gaggar Anuj | +14,000 | - | - |
| 2026-03-29 | White Nicole S | +14,000 | - | - |
| 2026-03-29 | Bjorkquist Jeanette M | +3,500 | - | - |
| 2026-03-29 | Delaney William E IV | +14,000 | - | - |
| 2026-03-29 | Okazaki Jason A | +50,750 | - | - |
| 2026-03-29 | Bjorkquist Jeanette M | +6,500 | - | - |
| 2026-03-29 | White Nicole S | +26,000 | - | - |
| 2026-03-29 | Gaggar Anuj | +26,000 | - | - |
| 2026-03-29 | Delaney William E IV | +26,000 | - | - |
| 2026-03-29 | Okazaki Jason A | +94,250 | - | - |